Evotec OAI and Guilford Pharmaceuticals in drug discovery agreement
Evotec OAI has entered into a drug discovery agreement with Guilford Pharmaceuticals, of Maryland in the US, to identify small molecule compounds that interact with selected Guilford targets.
Evotec OAI has entered into a drug discovery agreement with Guilford Pharmaceuticals, of Maryland in the US, to identify small molecule compounds that interact with selected Guilford targets.
Evotec OAI will provide an integrated biology solution including developing assays and screening them in an ultra-high throughput format against multiple Guilford targets.
Evotec OAI will apply its proprietary and validated screening technologies, its expertise and its screening library of 250,000 drug-like small molecule compounds. In addition, Evotec OAI will provide profiling services to Guilford to further characterise selected hits for progression. Evotec OAI will receive research fees for the activities performed and milestone payments on the successful pre-clinical development of the drug compounds and their approval for further clinical development.
'Early discovery and research will be one of the important engines of our pipeline,' said Dr Barbara Slusher, senior vice president of research and toxicology at Guilford. 'We believe that Evotec will play an important role in this effort.'